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Background: Patients may experience nausea and vomiting when undergoing chemotherapy or surgery requiring
anesthesia. Serotonin 5-hydroxytryptamine 3 (5-HT3) receptor antagonists are effective antiemetics, yet may cause
adverse cardiac events, such as arrhythmia. We aimed to identify interventions that mitigate the cardiac risk of
5-HT3 receptor antagonists.
Methods: Electronic databases, trial registries, and references were searched. Studies on patients undergoing
chemotherapy or surgery examining interventions to monitor cardiac risk of 5-HT3 receptor antagonists were
included. Search results were screened and data from relevant studies were abstracted in duplicate. Risk of
bias of included studies was assessed using the Cochrane Effective Practice and Organisation of Care (EPOC)
group’s risk-of-bias tool. Due to a dearth of included studies, meta-analysis was not conducted.
Results: Two randomized clinical trials (RCT) and 1 non-randomized clinical trial (NRCT) were included after
screening 7,637 titles and abstracts and 1,554 full-text articles. Intravenous administration of different dolasetron
doses was examined in the NRCT, while dolasetron versus ondansetron and palonosetron versus ondansetron
were examined in the RCT. Electrocardiogram (ECG) was the only intervention examined to mitigate cardiac
harm. No differences in ECG evaluations were observed between dolasetron or palonosetron versus ondansetron
after 15 minutes, 24 hours, and 1 week post-administration in the 2 RCTs. Four deaths were observed in one RCT, which
were deemed unrelated to palonosetron or ondansetron administration. Minor increases in PR and QT intervals were
observed in the NRCT for dolasetron dosages greater than 1.2 mg/kg 1–2 hours post-administration, but were deemed
not clinically relevant.
Conclusions: ECG monitoring of chemotherapy patients administered with 5-HT3 receptor antagonists did not reveal
clinically significant differences in arrhythmia between the medications at the examined time periods. The usefulness of
ECG to monitor chemotherapy patients administered with 5-HT3 receptor antagonists remains unclear, as all patients
received ECG monitoring.
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Nausea and vomiting are common adverse effects follow-
ing chemotherapy or surgery requiring anesthesia [1,2].
Serotonin 5-hydroxytryptamine 3 (5-HT3) receptor antag-
onists can effectively prevent nausea and vomiting for pa-
tients undergoing these interventions [1,3-5]. However, a
prolonged QT interval has been observed in previous
studies of these medications [6,7]. The results of these
studies suggest that patients who are administered 5-HT3
receptor antagonists might be at risk of experiencing car-
diac harm, yet this has not been confirmed in large-scale
studies or systematic reviews.
Diagnostic tests can be used to monitor or mitigate
cardiac risk that might be associated with 5-HT3 receptor
antagonist administration. For example, electrocardiogram
(ECG) provides information on PR and QT prolongation,
which may lead to arrhythmia (e.g., torsade de pointes
tachycardia) [8], all-cause mortality [9], and sudden death
[10]. Cardiac telemetry monitors provide continuous ECG
monitoring for 24 hours or longer [11]. Electrolyte imbal-
ances, such as hypocalcemia, hypomagnesemia and hypo-
kalemia can result from persistent vomiting and these
abnormalities can cause QT interval prolongation [12]. As
such, monitoring might be necessary in patients receiving
5-HT3 antagonists and who are vomiting. However, these
diagnostic tests are burdensome to the healthcare system
and patients. We aimed to determine whether diagnostic
interventions can be implemented to mitigate the risk of
adverse cardiac events associated with 5-HT3 receptor an-
tagonists for patients undergoing chemotherapy or sur-
gery through a systematic review.
Methods
We used the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) Statement to re-
port the results of our systematic review [13].
Protocol
We developed a protocol that was reviewed by clinicians,
systematic review methodologists, pharmacoepidemiolo-
gists, and Health Canada. We registered our protocol with
the PROSPERO database (CRD42013003565) and pub-
lished the final version [14].
Eligibility criteria
Studies were included if they examined interventions to
monitor cardiac risk associated with 5-HT3 receptor an-
tagonists, such as ECG monitoring, telemetry, adjust-
ment of antiarrhythmics, and electrolyte monitoring and
replacement. Studies including patients of all ages receiv-
ing 5-HT3 antagonist receptors for nausea and vomiting
symptoms post-surgery or after chemotherapy and report-
ing on arrhythmia (primary outcome), sudden cardiac
death, QT prolongation, PR prolongation, and/or all-causemortality were eligible for inclusion. Experimental studies
(randomized clinical trials, quasi-randomized clinical
trials, non-randomized clinical trials), quasi-experimental
studies (interrupted time series, controlled before and
after studies), and cohort studies were included regardless
of whether they were unpublished or written in languages
other than English.
Information sources and literature search
MEDLINE, EMBASE, and Cochrane Central were searched
from inception onwards. The electronic literature search
was supplemented by searching trial registers and scanning
the reference lists of included studies.
An experienced librarian drafted the search strategies,
which were peer reviewed by another expert librarian
using the Peer Review of Electronic Search Strategies
(PRESS) checklist [15]. The final literature search for
MEDLINE has been published previously [14] and is
available in the Additional file 1. Literature searches for
the other databases can be obtained from the corrspond-
ing author upon request.
Study selection process
The eligibility criteria were calibrated on a random sample
of 50 titles and abstracts from the literature search. They
were revised to enhance clarity and readability by the
team. Subsequently, each title and abstract was screened
by two team members, independently. Conflicts were re-
solved by team discussion. The same process was followed
for screening the potentially relevant full-text articles.
Data items and data collection process
Following a similar process to screening, two team
members independently abstracted data on study charac-
teristics (e.g., setting, country where the study was con-
ducted, details on the 5-HT3 medications, comparator
used, and type of test conducted to assess cardiac risk),
patient characteristics (e.g., mean/median age, percent fe-
male, type of surgery, type of cancer), and outcome results
(e.g., number of patients experiencing arrhythmia, mean
and standard deviation for PR prolongation). Companion
reports (i.e., duplicate publications reporting the data on
the same group of patients) were sorted and authors were
contacted for data clarifications.
Methodological quality/risk of bias appraisal
Studies were appraised using the Cochrane Effective
Practice and Organisation of Care Risk of Bias Tool [16]
and the McHarm tool for reporting adverse events [17].
Synthesis of included studies
We were unable to conduct meta-analysis because none
of the studies examined interventions to mitigate harm
at the same time point. Furthermore, none of the studies
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group. As such, the studies were synthesized descriptively,
with a focus on the study characteristics, patient charac-
teristics, and outcome results.
Results
Literature search
Two randomized clinical trials and 1 non-randomized
clinical trial [18-20] were included after screening 7,637
titles and abstracts and 1,554 full-text articles (Figure 1).
Study and patient characteristics
The study conduct period was 2000 and 2002 in the ran-
domized clinical trials [19,20] and not reported in theFigure 1 Study flow.non-randomized clinical trial [18] that was published in
1996 (Table 1). The trials were conducted in the United
States [18], multiple European countries [19], and South
Korea [20]. One trial examined intravenous dolasetron
at 1.2, 1.8, and 2.4 mg/kg administered 30 minutes prior
to chemotherapy [18] and another examined intravenous
palonosetron 0.25 to 0.75 mg compared to ondansetron
32 mg administered 30 minutes prior to chemotherapy
[19]. The third trial examined the effects of intravenous
dolasetron 100 mg administered 30 minutes prior to
chemotherapy and up to 200 mg orally 2 to 5 days post-
chemotherapy compared with another group who received
8 mg of intravenous ondansetron 30 minutes prior to
chemotherapy and up to 16 mg intravenously 2–4 hours
Table 1 Study characteristics






Hesketh [18] NR, USA Non-RCT, 44 IV dolasetron 1.2 mg/kg, 1.8 mg/kg,
2.4 mg/kg 30 mins before chemotherapy
ECG, 1–2 hrs and 24–48 hrs PR, QT
Gralla [19] August 2000 to October 2001,
Germany, Italy, UK,
Netherlands, Russia
RCT, 98 IV palonosetron 0.25 mg, IV palonosetron
0.75 mg, IV ondansetron 32 mg 30 mins
before chemotherapy
ECG, 15 mins, 24 hrs, 1 wk Mortality, QT
Kim [20] April 2002 to October 2002,
South Korea
RCT, 114 IV dolasetron 100 mg 30 mins before and
200 mg p.o. 2-5 days after chemotherapy,
IV ondansetron 8 mg 30 mins before and
IV ondansetron 16 mg 2–4 hrs plus an
additional 16 mg/day p.o. 2-5 days after
chemotherapy
ECG, 15 mins, 24 hrs, 1 wk ECG findings
unspecified
ECG: electrocardiogram; IV: intravenous; NR: not reported; Non-RCT: non-randomized clinical trial; p.o.: administered orally; RCT: randomized controlled trial.
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days after chemotherapy.
The only intervention identified to mitigate cardiac
risk that was examined in the trials was an ECG at various
time points. ECG monitoring was not compared with pla-
cebo, usual care or another type of diagnostic interven-
tion. The percentage of females included in the trials
ranged from 37 to 72% (Table 2). All trials included adult
cancer patients with a median (or mean) age ranging from
54 to 56 years. All were receiving a 5-HT3 receptor antag-
onist for their chemotherapy treatment for various cancer
sites. Patients were receiving a variety of chemotherapeu-
tic agents.
Risk of bias assessment
All of the included trials received the same intervention
(ECG monitoring) without a comparator group and were
assessed for risk of bias (Table 3). The non-randomized
clinical trial had the highest risk of bias, with four items
assessed as having a high risk of bias [18]. One of the
randomized trials had a high risk of bias for allocation
concealment and blinding and an unclear risk of bias for
random sequence generation and contamination [20]. The
other randomized trial had an unclear risk of bias for ran-
dom sequence generation, contamination, and selective
outcome reporting [19]. All of the other risk of bias cri-
teria was assessed as unclear.Table 2 Patient characteristics
Reference % female Mean age in years
(SD) [range]
Cancer site (%)
Hesketh [18] 71 Median 54 (NR)
[25–81]
Breast (55), other (45)
Gralla [19] 72 55 (11) [18-NR] Breast (57), lung (80 < blad
rectal (3), small-cell lung (3
Kim [20] 37 55.6 (11) [18-NR] Lung (26), gastric (11), othe
NR: not reported; SD: standard deviation. *received by >10% of patients.Arrhythmia
None of the included trials reported data on arrhythmia,
our primary outcome of interest. However, all three tri-
als reported no clinically relevant differences in ECG
findings among the patients receiving the 5-HT3 recep-
tor antagonists examined.
Sudden cardiac death and all-cause mortality
Mortality was reported in one of the trials [19]. One with-
drawal due to a serious adverse event (pulmonary embol-
ism resulting in death) occurred in the ondansetron group
and three other deaths occurred, yet the number of deaths
per treatment group was not reported. All deaths were
deemed as unlikely or definitely unrelated to the study
medications [19]. Although mortality was not specifically
reported, no patients dropped out due to mortality in the
other two trials [18,20].
QT prolongation
One trial reported no differences between treatment
groups in the mean post-dose change from baseline in
the QT interval, which was adjusted using the Fridericia
correction [19]. The values were 1 ms for palonosetron
0.25 mg, 2 ms for palonosetron 0.75 mg, and 5 ms for
ondansetron. Another trial reported median increases in
the corrected QT interval as being 11 ms for dolasetron
1.2 mg/kg, 27 ms for dolasetron 1.8 mg/kg, and 39 msCommon chemotherapeutic agents* (%)
Doxorubicin (15), cyclophosphamide (26),
5-FU (43), vincristine (23), methotrexate (14)
der (5), colon (4),
), gastric (3)
Cyclophosphamide (63), doxorubicin (48),
cisplatin (18), methotrexate (16), carboplatin (12)
r (29) 5-FU plus cisplatin (27), cisplatin plus the following:
taxol, docetaxel, etoposide and ifosfomide, etoposide,
gemcitabine, docetaxel plus 5-FU (73)
Table 3 Appraisal of risk of bias, according to Cochrane
Effective Practice and Organization of Care risk-of-bias
tool [16]
Criterion Hesketh [18] Gralla [19] Kim [20]
Random sequence generation High Unclear Unclear




Similar baseline characteristics Low Low Low
Incomplete outcome data Low Low Low
Blinding High Low High
Contamination Unclear Unclear Unclear
Selective outcome reporting Unclear Unclear Unclear
Other bias High Low Low
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tomatic and not clinically significant. The third trial did
not specifically report on this outcome but reported no
relevant differences between the treatment groups with re-
spect to ECG findings [20] (Table 4).
PR prolongation
One trial reported median increases in the PR interval
as being 1 ms for dolasetron 1.2 mg/kg, 10 ms for dola-
setron 1.8 mg/kg, and 22 ms for dolasetron 2.4 mg/kg
[18]. A significant dose–response relationship was found
between dolasetron and the PR interval at 1–2 hours
post-administration. These changes were considered
asymptomatic and not clinically significant. The otherTable 4 QT and PR prolongation








QT prolongation* 11 ms 27 ms 39 ms








QT prolongation* 1 ms 2 ms 5 ms






(8 mg, BC +
80 mg, AC)
QT prolongation NS NS
PR prolongation NS NS
AC: after chemotherapy treatment; BC: before the start of chemotherapy
treatment; NS: not significant. *mean change from baseline; †median change
from baseline.trials did not specifically report on this outcome but reported
no relevant differences between the treatment groups with
respect to ECG findings [19,20] (Table 4).
Discussion
In our systematic review, we did not find any clinically
relevant changes in the QT interval between different
dosages of dolasetron [18] or between palonosetron and
ondansetron [19] or dolasetron and ondansetron [20].
Furthermore, we did not find any other significant differ-
ences in other ECG changes between these 5-HT3 recep-
tor antagonists at 15 minutes, 1–2 hours, 24 hours, and
1 week post-administration. However, this does not sug-
gest that these agents do not cause cardiac harm. For ex-
ample, two case series have noted a prolonged QT interval
after the administration of 5-HT3 receptor antagonists
[6,7]. Both articles were excluded here because they were
case series and therefore there was not a comparison
group and they did not examine interventions to mitigate
the cardiac risk associated with these agents.
We had originally hoped to identify studies in which all
patients received a 5-HT3 receptor antagonist and com-
pared an intervention to mitigate cardiac harm (e.g., ECG
monitoring) with placebo, usual care or another diagnostic
intervention. As we did not identify any such study, the
utility of the ECG to monitor adult chemotherapy patients
after being administered a 5-HT3 receptor antagonist is
currently unclear. Further research is required to recom-
mend ECG monitoring for all adult chemotherapy pa-
tients administered a 5-HT3 receptor antagonist, as this
would be burdensome to the healthcare system and to
patients.
We identified many gaps in the literature in this area.
For example, we did not identify studies that tested moni-
toring cardiac function after the administration of these
agents other than the ECG. Similarly, we did not identify
studies conducted among children receiving chemother-
apy or patients of any age undergoing surgery requiring
anesthesia and none of the included studies reported the
proportion of patients with prolonged QT or PR intervals.
Although unpublished studies were sought, none were
identified that examined this research question.
As expected, the non-randomized clinical trial had the
greatest risk of bias [18], as random sequence generation,
allocation concealment, and blinding was not conducted.
The two randomized clinical trials would be improved by
adequately reporting random sequence generation, report-
ing whether contamination was a factor, and providing a
protocol so that the potential for outcome reporting bias
could be assessed [19,20]. Limitations of our systematic re-
view process include the few studies identified for inclu-
sion. As well, our objective was to compare interventions
to mitigate cardiac risk across intervention and comparator
groups versus examine cardiac risk after the administration
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ports, and cross-sectional studies. We were unable to con-
duct meta-analysis or assess for publication bias because
of the few studies included here.
Conclusions
The utility of the ECG monitoring to mitigate cardiac
harm among chemotherapy patients after being adminis-
tered a 5-HT3 receptor antagonist is unclear; few studies
exist that met our eligibility criteria. Future research is ne-
cessary to determine whether ECG (or other diagnostic in-
terventions) are beneficial and whether these interventions
should be used to monitor other patient populations, in-
cluding children undergoing chemotherapy and patients of
all ages receiving surgery requiring anesthesia.Additional file
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